These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 21147840)

  • 1. PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease.
    Yoshihara D; Kurahashi H; Morita M; Kugita M; Hiki Y; Aukema HM; Yamaguchi T; Calvet JP; Wallace DP; Nagao S
    Am J Physiol Renal Physiol; 2011 Feb; 300(2):F465-74. PubMed ID: 21147840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telmisartan ameliorates fibrocystic liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease.
    Yoshihara D; Kugita M; Sasaki M; Horie S; Nakanishi K; Abe T; Aukema HM; Yamaguchi T; Nagao S
    PLoS One; 2013; 8(12):e81480. PubMed ID: 24324698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PPAR-γ agonists in polycystic kidney disease with frequent development of cardiovascular disorders.
    Nagao S; Yamaguchi T
    Curr Mol Pharmacol; 2012 Jun; 5(2):292-300. PubMed ID: 22122459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate.
    Masyuk TV; Masyuk AI; Torres VE; Harris PC; Larusso NF
    Gastroenterology; 2007 Mar; 132(3):1104-16. PubMed ID: 17383431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renin-angiotensin system activation in congenital hepatic fibrosis in the PCK rat model of autosomal recessive polycystic kidney disease.
    Goto M; Hoxha N; Osman R; Wen J; Wells RG; Dell KM
    J Pediatr Gastroenterol Nutr; 2010 Jun; 50(6):639-44. PubMed ID: 20400910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B-type natriuretic peptide overexpression ameliorates hepatorenal fibrocystic disease in a rat model of polycystic kidney disease.
    Holditch SJ; Schreiber CA; Harris PC; LaRusso NF; Ramirez-Alvarado M; Cataliotti A; Torres VE; Ikeda Y
    Kidney Int; 2017 Sep; 92(3):657-668. PubMed ID: 28416225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global Gene Expression Profiling in PPAR-γ Agonist-Treated Kidneys in an Orthologous Rat Model of Human Autosomal Recessive Polycystic Kidney Disease.
    Yoshihara D; Kugita M; Yamaguchi T; Aukema HM; Kurahashi H; Morita M; Hiki Y; Calvet JP; Wallace DP; Toyohara T; Abe T; Nagao S
    PPAR Res; 2012; 2012():695898. PubMed ID: 22666229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Mast Cell Degranulation With Cromolyn Sodium Exhibits Organ-Specific Effects in Polycystic Kidney (PCK) Rats.
    Jiang L; Fang P; Septer S; Apte U; Pritchard MT
    Int J Toxicol; 2018; 37(4):308-326. PubMed ID: 29862868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic treatment with lisinopril decreases proliferative and apoptotic pathways in autosomal recessive polycystic kidney disease.
    Jia G; Kwon M; Liang HL; Mortensen J; Nilakantan V; Sweeney WE; Park F
    Pediatr Nephrol; 2010 Jun; 25(6):1139-46. PubMed ID: 20229187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The PPARgamma agonist pioglitazone ameliorates aging-related progressive renal injury.
    Yang HC; Deleuze S; Zuo Y; Potthoff SA; Ma LJ; Fogo AB
    J Am Soc Nephrol; 2009 Nov; 20(11):2380-8. PubMed ID: 19797472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pioglitazone, a Peroxisome Proliferator-Activated Receptor x03B3; Agonist, Ameliorates Chronic Kidney Disease by Enhancing Antioxidative Capacity and Attenuating Angiogenesis in the Kidney of a 5/6 Nephrectomized Rat Model.
    Sun L; Yuan Q; Xu T; Yao L; Feng J; Ma J; Wang L; Lu C; Wang D
    Cell Physiol Biochem; 2016; 38(5):1831-40. PubMed ID: 27160248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial evaluation of hepatic T1 relaxation time as an imaging marker of liver disease associated with autosomal recessive polycystic kidney disease (ARPKD).
    Gao Y; Erokwu BO; DeSantis DA; Croniger CM; Schur RM; Lu L; Mariappuram J; Dell KM; Flask CA
    NMR Biomed; 2016 Jan; 29(1):84-9. PubMed ID: 26608869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease stage characterization of hepatorenal fibrocystic pathology in the PCK rat model of ARPKD.
    Mason SB; Liang Y; Sinders RM; Miller CA; Eggleston-Gulyas T; Crisler-Roberts R; Harris PC; Gattone VH
    Anat Rec (Hoboken); 2010 Aug; 293(8):1279-88. PubMed ID: 20665806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rosiglitazone attenuates development of polycystic kidney disease and prolongs survival in Han:SPRD rats.
    Dai B; Liu Y; Mei C; Fu L; Xiong X; Zhang Y; Shen X; Hua Z
    Clin Sci (Lond); 2010 Jul; 119(8):323-33. PubMed ID: 20507283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feeding soy protein isolate and n-3 PUFA affects polycystic liver disease progression in a PCK rat model of autosomal polycystic kidney disease.
    Maditz KH; Benedito VA; Oldaker C; Nanda N; Lateef SS; Livengood R; Tou JC
    J Pediatr Gastroenterol Nutr; 2015 Apr; 60(4):467-73. PubMed ID: 25822773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biliary dysgenesis in the PCK rat, an orthologous model of autosomal recessive polycystic kidney disease.
    Masyuk TV; Huang BQ; Masyuk AI; Ritman EL; Torres VE; Wang X; Harris PC; Larusso NF
    Am J Pathol; 2004 Nov; 165(5):1719-30. PubMed ID: 15509540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroxisome proliferator-activated receptor-γ agonist pioglitazone fails to attenuate renal fibrosis caused by unilateral ureteral obstruction in mice.
    Zhang Y; Wang J; Zhou QD; Zhang CH; Li Q; Huang S; Zhan J; Wang K; Liu YY; Xu G
    J Huazhong Univ Sci Technolog Med Sci; 2016 Feb; 36(1):41-47. PubMed ID: 26838738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease.
    Masyuk TV; Radtke BN; Stroope AJ; Banales JM; Masyuk AI; Gradilone SA; Gajdos GB; Chandok N; Bakeberg JL; Ward CJ; Ritman EL; Kiyokawa H; LaRusso NF
    Gastroenterology; 2012 Mar; 142(3):622-633.e4. PubMed ID: 22155366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation.
    Ohga S; Shikata K; Yozai K; Okada S; Ogawa D; Usui H; Wada J; Shikata Y; Makino H
    Am J Physiol Renal Physiol; 2007 Apr; 292(4):F1141-50. PubMed ID: 17190910
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.